Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. paralysis
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Books
Downloads
Videos

Refine by
Date

  • Older

Paralysis Articles & Analysis: Older

36 news found

Eikonoklastes Therapeutics and Forge Biologics Announce Viral Vector Contract Development and AAV Manufacturing Partnership

Eikonoklastes Therapeutics and Forge Biologics Announce Viral Vector Contract Development and AAV Manufacturing Partnership

Degeneration of these neurons leads to paralysis as the brain loses its ability to control muscle movement. Most people with ALS succumb to respiratory failure, usually within three to five years from when symptoms first appear. ...

ByForge Biologics, Inc.


Bayer initiates landmark Phase III study program to investigate oral FXIa inhibitor asundexian

Bayer initiates landmark Phase III study program to investigate oral FXIa inhibitor asundexian

Stroke may result in severely restricted movement, paralysis, loss of speech or vision, which may be permanent, or even death. ...

ByBayer AG


Synchron Announces First Human U.S. Brain-Computer Interface Implant

Synchron Announces First Human U.S. Brain-Computer Interface Implant

“The first-in-human implant of an endovascular BCI in the U.S. is a major clinical milestone that opens up new possibilities for patients with paralysis,” said Tom Oxley, MD, PhD, CEO & Founder, Synchron. ...

BySynchron, Inc.


Synchron Appoints Kurt Haggstrom as Chief Commercial Officer

Synchron Appoints Kurt Haggstrom as Chief Commercial Officer

“I am honored and excited to join the Synchron team and be part of this amazing journey to help the millions of people worldwide who suffer from paralysis,” said Kurt Haggstrom, Chief Commercial Officer, Synchron. ...

BySynchron, Inc.


Team Gleason Partners with Synchron to Redefine Accessibility

Team Gleason Partners with Synchron to Redefine Accessibility

The system is designed for patients suffering from paralysis as a result of a broad range of conditions, and aims to be user friendly and dependable for patients to use autonomously. ...

BySynchron, Inc.


Citrine Medicine Announces Approval of Wakix (pitolisant) for Named Patient Program in China

Citrine Medicine Announces Approval of Wakix (pitolisant) for Named Patient Program in China

Cataplexy is characterized by sudden and uncontrolled muscle weakness or paralysis. Pitolisant has an orphan designation in the EU and the US for the treatment of narcolepsy. ...

ByRareStone Group


Synchron Announces Enrollment of First Patient in U.S. Endovascular Brain Computer Interface Study COMMAND in Patients With Severe Paralysis

Synchron Announces Enrollment of First Patient in U.S. Endovascular Brain Computer Interface Study COMMAND in Patients With Severe Paralysis

Synchron and Mount Sinai Hospital in New York Advance Industry-First FDA-Approved Clinical Trial for Brain-Computer Interface in U.S. Paralysis is a devastating condition for more than 5 million patients in the United States Synchron, an endovascular brain-computer (BCI) interface company, today announced the enrollment of the first patient in the US clinical trial, ...

BySynchron, Inc.


Synchron Announces Long-Term Safety Results from Fully Implanted Endovascular Brain-Computer Interface Stentrode for Severe Paralysis

Synchron Announces Long-Term Safety Results from Fully Implanted Endovascular Brain-Computer Interface Stentrode for Severe Paralysis

“Years of research and technological development culminated in this moment, and as we continue to develop our technology, it has the potential to change the lives of millions of patients globally who suffer from paralysis and other debilitating neurological and brain-related ...

BySynchron, Inc.


Synchron Expands Advisory Board as Brain-Computer Interface Device Stentrode Advances into Patients in US Clinical Trials

Synchron Expands Advisory Board as Brain-Computer Interface Device Stentrode Advances into Patients in US Clinical Trials

“I’m both honored and thrilled to work with Edward, Max, Jordi and Earl, who will play an invaluable role in guiding our strategic decisions as we advance our endovascular brain computer interface to treat individuals with a significant unmet medical need, beginning with patients with severe paralysis.” Synchron has developed an endovascular brain computer ...

BySynchron, Inc.


Synchron announces first direct-thought tweet, “Hello World,”using an implantable brain computer interface

Synchron announces first direct-thought tweet, “Hello World,”using an implantable brain computer interface

Philip received the endovascular Stentrode brain computer interface in April 2020 following progressive paralysis caused by ALS which left him unable to engage in work-related or other independent activities. ...

BySynchron, Inc.


ClearPoint Neuro Congratulates Blackrock Neurotech on Receiving Breakthrough Device Designation from the FDA for the MoveAgain Brain-Computer Interface System

ClearPoint Neuro Congratulates Blackrock Neurotech on Receiving Breakthrough Device Designation from the FDA for the MoveAgain Brain-Computer Interface System

There are an estimated 5.35 million1 people in the United States who suffer from paralysis due to central nervous system disorders, autoimmune diseases, and spinal cord injuries. ...

ByClearPoint Neuro, Inc.


RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team

RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team

These include two cell therapies - one for skin rejuvenation and one for tendon regeneration - and a next-generation dermal injector (DermaPrecise™) for aesthetic treatments involving a wide variety of injectable substances including cells, PRP, muscle paralysis toxins, fillers, enzymes, drugs, and other biologics. RepliCel’s cell therapy technology is the subject of ...

ByRepliCel Life Sciences


Flat Medical announced FDA 510(k) clearance of EpiFaith, the Epidural Safety Solution

Flat Medical announced FDA 510(k) clearance of EpiFaith, the Epidural Safety Solution

Compared with traditional practice that relies on the manual sense, EpiFaith® provides intuitive signal that tells anesthesiologists the arrival of epidural space, thus prevent the accidental puncture to dura, avoiding the risk of serious headache, paralysis, prolonged admission time, and related healthcare costs. “Post-dural puncture headache is a complication which ...

ByFlat Medical


Synchron receives green light from FDA to begin breakthrough trial of implantable brain computer interface in US

Synchron receives green light from FDA to begin breakthrough trial of implantable brain computer interface in US

Our first target is the motor cortex for treatment of paralysis, which represents a large unmet need for millions of people across the world, and market opportunity of ...

BySynchron, Inc.


RepliCel Applies for Manufacturing Approval for its Collagen and Tissue Regeneration Cell Therapies

RepliCel Applies for Manufacturing Approval for its Collagen and Tissue Regeneration Cell Therapies

These include two cell therapies - one for skin rejuvenation and one for tendon regeneration - and a next-generation dermal injector for aesthetic treatments involving a wide variety of injectable substances including cells, PRP, muscle paralysis toxins, fillers, enzymes, drugs, other biologics, etc. The RepliCel cell therapy technology which is the subject of active, ongoing ...

ByRepliCel Life Sciences


Alume Biosciences Granted FDA Fast Track Designation of ALM-488 for Surgical Nerve Visualization

Alume Biosciences Granted FDA Fast Track Designation of ALM-488 for Surgical Nerve Visualization

Inadvertent nerve injury during surgical procedures can cause significant morbidity including numbness, paralysis, urinary incontinence and erectile dysfunction, depending on the clinical setting. ...

ByAlume Biosciences, Inc.


Neurolutions Receives U.S. Food and Drug Administration De Novo Market Authorization for IpsiHand

Neurolutions Receives U.S. Food and Drug Administration De Novo Market Authorization for IpsiHand

Approximately 800,000 American adults experience a stroke each year, of which approximately 300,000 are left with upper extremity movement dysfunction. Muscular weakness or partial paralysis frequently persists into the chronic stage of stroke with 65% of chronic stroke patients reporting reduced motor function six months after stroke. ...

ByNeurolutions


Neurolutions IpsiHand Stroke Rehabilitation Device Authorized by FDA

Neurolutions IpsiHand Stroke Rehabilitation Device Authorized by FDA

Although stroke is a brain disease, it can affect the entire body and sometimes causes long-term disability such as complete paralysis of one side of the body (hemiplegia) or one-sided weakness (hemiparesis) of the body. ...

ByNeurolutions


Neuraptive Therapeutics Announces FDA Clearance of a Second IND Application for NTX-001 in the Prevention of Postoperative Facial Paralysis and Plans to Initiate a Phase 2 Clinical Study Later This Year

Neuraptive Therapeutics Announces FDA Clearance of a Second IND Application for NTX-001 in the Prevention of Postoperative Facial Paralysis and Plans to Initiate a Phase 2 Clinical Study Later This Year

Neuraptive plans to conduct a Phase 2 Multicenter, Randomized, Controlled Study Evaluating the Safety and Efficacy of NTX-001 versus Standard of Care in Treatment and Prevention of Facial Paralysis Requiring Surgical Repair. Neuraptive Therapeutics, Inc. ...

ByNeuraptive Therapeutics, Inc.


Alexion Announces Upcoming Data Presentations at the 73rd Annual Meeting of the American Academy of Neurology

Alexion Announces Upcoming Data Presentations at the 73rd Annual Meeting of the American Academy of Neurology

The most common symptoms of NMOSD are optic neuritis, which can cause visual problems including blindness, and transverse myelitis, which can cause mobility problems including paralysis. The disease primarily affects women, with an average age of onset of 39 years. ...

ByAlexion Pharmaceuticals, Inc.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT